Enliven Therapeutics Inc. News
Latest updates and market news for ELVN
3 news
Jan 8 - Jan 14, 2026
Page 1
MT Newswires
Enliven Therapeutics Leukemia Drug Achieves 69% Response Rate in Phase 1b Trial
➖
AI Sentiment
Neutral
5/10
PR Newswire
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
📈
AI Sentiment
Highly Positive
9/10
Share this news page